Is an alternative to glycopeptides for treating methicillin-resistant Staphylococcus aureus infections available?;Existe-t-il une alternative aux glycopeptides pour le traitement des infections à Staphylococcus aureus résistant à la méthicilline ?

Reanimation

Volumn 15, Issue 3, 2006, Pages 176-179

  Carlet, J ^a   Benali, A ^a  

^a SAINT JOSEPH HOSPITAL   (France)

Author keywords

Glycopeptides; Linezolid; Lipopeptides; Resistance; Staphylococcus aureus; Tigecyclin

Indexed keywords

CEFTOBIPROLE; CEPHALOSPORIN; CYCLINE; DALBAVANCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; FOSFOMYCIN; GENTAMICIN; GLYCOPEPTIDE; LINEZOLID; LIPOPEPTIDE; ORITAVANCIN; RIFAMPICIN; TIGECYCLINE; VANCOMYCIN;

FRANCE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PREVALENCE; SHORT SURVEY; STAPHYLOCOCCUS INFECTION;

EID: 33646803792     PISSN: 16240693     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.reaurg.2006.03.005     Document Type: Short Survey

References (19)

1. European antimicrobial resistance surveillance system (EARSS). Annual report 2004. Available from: http://www.rivm.nl/ears.
2. Lucet J.C., Paoletti X., Lolom I., Paugam-Burzt C., Trouillet J.L., Timsit J.F., et al. Successful long-term program for controlling methicillin-resistant Staphylococcus aureus in intensive care units. Intensive Care Med. 31 (2005) 1051-1057
3. Mainardi J.L., Shlaes D.M., Goering R.V., Shlaes J.H., Acar J.F., and Goldstein F.W. Decreased teicoplanin susceptibility of methicillin-resistant strains of Staphylococcus aureus. J. Infect. Dis. 171 (1995) 1646-1650
4. Begier E.M., Frenette K., Barrett N.L., Mshar P., Petit S., Boxrud D.J., et al. A high-morbidity outbreak of methicillin-resistant Staphylococcus aureus among players on a college football team, facilitated by cosmetic body shaving and turf burns. Clin. Infect. Dis. 39 (2004) 1446-1453
5. Fridkin S.K., Hageman J.C., Morrison M., Sanza L.T., Como-Sabetti K., Jemigan J.A., et al. Methicillin-resistant Staphylococcus aureus disease in three communities. N. Engl. J. Med. 352 (2005) 1436-1444
6. Miller L.G., Perdreau-Remington F., Rieg G., Mehdi S., Perlroth J., Bayer A.S., et al. Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles. N. Engl. J. Med. 352 (2005) 1445-1453
7. Robinson D.A., Kearns A.M., Holmes A., Morrison D., Grundmann H., Edwards G., et al. Re-emergence of early pandemic Staphylococcus aureus as a community-acquired methicillin-resistant clone. Lancet 365 (2005) 1256-1258
8. Kravitz G.R., Dries D.J., Peterson M.L., and Schlievert P.M. Purpura fulminans due to of Staphylococcus aureus. Clin. Infect. Dis. 40 (2005) 941-947
9. Jacqueline C., Asseray N., Batard E., Miegeville A.F., Le Mabecque C., Kergueris M.F., et al. In vivo efficacy of linezolid in combination with gentamicin for the treatment of experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Int. J. Antimicrob. Agents 24 (2004) 393-396
10. Kasiakou S.K., Sermaides G.J., Michalopoulos A., Soteriades E.S., and Falagas M.E. Continuous vs intermittent intravenous administration of antibiotics: a meta-analysis of randomised controlled trials. Lancet Infect. Dis. 5 (2005) 581-589
11. Mehrotra R., De Gaudio R., and Palazzo M. Antibiotic pharmacokinetic and pharmacodynamic considerations in critical illness. Intensive Care Med. 30 (2004) 2145-2156
12. Wysocki M., Delatour F., Faurisson F., Rauss A., Pean Y., Misset B., et al. Continuous vs intermittent infusion of vancomycin in severe staphylococcal infections: prospective multicenter randomised study. Antimicrob. Agents Chemother. 45 (2001) 2460-2467
13. Jacqueline C., Batard E., Perez L., Boutoille D., Hamel A., Caillon J., et al. In vivo efficacy of continuous infusion vs intermittent dosing of linezolid compared to vancomycin in a methicillin-resistant Staphylococcus aureus rabbit endocarditis model. Antimicrob. Agents Chemother. 46 (2002) 3706-3711
14. Kitzis M.D., and Goldstein F.W. Monitoring of vancomycin serum levels for the treatment of staphylococcal infections. Clin. Microbiol. Infect. 12 (2006) 81-95
15. Boselli E., Breilh D., Pharm D., Djabarouti S., Toutain J., Chassard D., et al. Pharmacokinetics and intrapulmonary concentrations of linezolid administered to critically ill patients with ventilator-associated pneumonia. Crit. Care Med. 33 (2005) 1529-1533
16. Kollef M.H., Rello J., Cammarata S.K., Croos-Dabrera R.V., and Wunderink R.G. Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin. Intensive Care Med. 30 (2004) 388-394
17. Sacchidanand S., Penn R.L., Embil J.M., Campos M.E., Curcio D., Ellis-Grosse E., et al. Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: results from a phase 3, randomized, double-blind trial. Int. J. Inf. Dis. 9 (2005) 251-261
18. Hebeisen P., Heinze-Krauss I., Angehrn P., Hohl P., Page M.G., and Then R.L. In vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci. Antimicrob. Agents Chemother. 45 (2001) 825-836
19. Chambers H.F. Evaluation of ceftobiprole in a rabbit model of aortic valve endocarditis due to methicillin-resistant and vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 49 (2005) 884-888